ISSN: 1522-4821

Journal international sur la santé mentale d'urgence et la résilience humaine

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Nicotine Addiction in Schizophrenia, Availability of Better Treatment Options as are in General Population

Saeed Ahmed, MD, Samreen Ahmed, Washdave, Reena MD, Nuzhat Hussain, MD, Rizwan Ahmed and Sharmeen Amin

This article reviews literature regarding smoking cessation in Schizophrenia population, its harmful effects on health, finances, role of mental health care providers and better available options for treatment as are in general population. This population not only smokes at higher rates, but also has higher nicotine dependence with lower cessation rates than general population, people of schizophrenia have truncated life span due to smoking related diseases and premature mortality compared with the general population. Contrary to traditional reasoning that this population is not motivated or able to tolerate smoking cessation, but there is extensive literature that negates such rationale, even provides better treatment options to address this huge public health burden. Our review will mainly focusing treatment options particularly drug Varenicline, that shows most effective and promising results in patients of schizophrenia for smoking cessation as in general population, moreover different combination therapies, few new interventions, as well as some clinical areas will be discussed those need to be studied further in future.